ZK70 Stock Overview

A clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. More details

ZK70 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Risk Analysis

Negative shareholders equity

Makes less than USD$1m in revenue ($0)

Shareholders have been substantially diluted in the past year

Does not have a meaningful market cap (€1M)

+ 1 more risk

My Notes

Capture your thoughts, links and company narrative

Conduit Pharmaceuticals Inc. Competitors

co.don

XTRA:CNW

€6.5m

bioXXmed

XTRA:T5O

€490.1k

TFF Pharmaceuticals

MUN:0K30

€9.7m

Level Bio

NGM:LEVBIO

SEK 22.1m

Price History & Performance

Summary of share price highs, lows and changes for Conduit Pharmaceuticals
Historical stock prices
Current Share Price	US$3.09
52 Week High	US$28.00
52 Week Low	US$3.05
Beta	2.16
1 Month Change	-49.39%
3 Month Change	-65.89%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-86.92%

Recent updates

Shareholder Returns

	ZK70	DE Life Sciences	DE Market
7D	0%	-2.1%	-1.3%
1Y	n/a	-5.8%	14.9%

Return vs Industry: Insufficient data to determine how ZK70 performed against the German Life Sciences industry.

Return vs Market: Insufficient data to determine how ZK70 performed against the German Market.

Price Volatility

Is ZK70's price volatile compared to industry and market?
ZK70 volatility
ZK70 Average Weekly Movement	39.4%
Life Sciences Industry Average Movement	6.8%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.6%
10% least volatile stocks in DE Market	2.5%

Stable Share Price: ZK70's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: ZK70's weekly volatility has increased from 32% to 39% over the past year.

About the Company

Founded	Employees	CEO	Website
2019	7	Dave Tapolczay	www.conduitpharma.com

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave’s disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It has strategic services agreement with formulation development CDMO Agility Life Sciences to develop new solid oral-dosage form products.

Conduit Pharmaceuticals Inc. Fundamentals Summary

How do Conduit Pharmaceuticals's earnings and revenue compare to its market cap?
ZK70 fundamental statistics
Market cap	€1.36m
Earnings (TTM)	-€14.52m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.1x

P/E Ratio

Is ZK70 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ZK70 income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$15.15m
Earnings	-US$15.15m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-12.64
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	-26.4%

How did ZK70 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/20 15:32
End of Day Share Price	2025/01/28 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Conduit Pharmaceuticals Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.